Effects of cisatracurium on epithelial‑to‑mesenchymal transition in esophageal squamous cell carcinoma

Lv, Wenyan; Wang, Jingyu; Zhang, Shubao

doi:10.3892/ol.2019.10859

Cited by 7 publications

(7 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The protein expression levels of eMT-related proteins were determined using western blot analysis. Silencing of PITPNA-AS1 significantly decreased the protein expression levels of n-cadherin (n-cad) and vimentin (vim), which are important mesenchymal marker genes (14), while it enhanced the expression of e-cadherin (e-cad), which is a crucial epithelial marker (Fig. 4) (15).…”

Section: Pitpna-as1 Silencing Reduces Invasion Migration and Epithelmentioning

confidence: 99%

Long non‑coding RNA PITPNA‑AS1 silencing suppresses proliferation, metastasis and epithelial‑mesenchymal transition in non‑small cell lung cancer cells by targeting microRNA‑32‑5p

Chen

Zheng²,

et al. 2021

Mol Med Rep

View full text Add to dashboard Cite

lung cancer is one of the most common types of cancer and has a high mortality rate, worldwide. The major histopathological subtype is non-small cell lung cancer (nSclc). The aim of the present study was to investigate the role of long non-coding (lnc) rna PiTPna antisense rna 1 (PiTPna-aS1) in nSclc and elucidate its potential mechanisms. The expression of PiTPna-aS1 was determined in several nSclc cell lines. Following PiTPna-aS1-silencing, cell proliferation, invasion and migration were evaluated using cell counting Kit-8, colony formation, Transwell assay and wound healing assays, respectively. The expression levels of proliferation-, migration-and epithelial-mesenchymal transition (eMT)-associated proteins were examined using immunofluorescence assay or western blot analysis. a luciferase reporter assay was conducted to verify the potential interaction between PiTPna-aS1 and microrna(mir)-32-5p. Subsequently, rescue assays were performed to investigate the effects of PiTPna-aS1 and mir-32-5p on nSclc progression. The results demonstrated that PiTPna-aS1 was highly expressed in nSclc tissues and cell lines. it was found that PiTPna-aS1 silencing inhibited the proliferation, invasion and migration of nSclc cells. Furthermore, the protein expression of e-cadherin was upregulated, while the expression levels n-cadherin and vimentin were downregulated. The luciferase reporter assay confirmed that miR-32-5p was a direct target of PITPNA-AS1. The rescue experiments suggested that a mir-32-5p inhibitor significantly reversed the inhibitory effects of PITPNA-AS1 silencing on proliferation, invasion, migration and eMT in nSclc cells. collectively, the present results demonstrated that PiTPna-aS1 silencing could suppress the progression of nSclc by targeting mir-32-5p, suggesting a promising biomarker in nSclc diagnosis and treatment.

show abstract

Section: Pitpna-as1 Silencing Reduces Invasion Migration and Epithelmentioning

confidence: 99%

Long non‑coding RNA PITPNA‑AS1 silencing suppresses proliferation, metastasis and epithelial‑mesenchymal transition in non‑small cell lung cancer cells by targeting microRNA‑32‑5p

Chen

Zheng²,

et al. 2021

Mol Med Rep

View full text Add to dashboard Cite

show abstract

“…Following treatment with cisatracurium besilate and pifithrin-α, the apoptosis of AGS cells was evidently decreased compared with that in cisatracurium besilate-treated cells, suggesting that cisatracurium besilate enhanced AGS cell apoptosis by regulating p53. Consistently, cisatracurium besilate triggered apoptosis in human colorectal cancer cells via the p53 intrinsic apoptotic pathway [ 12 ]. Subsequently, the synergistic effects of TRAIL and cisatracurium besilate on AGS cell apoptosis were assessed.…”

Section: Discussionmentioning

confidence: 96%

Cisatracurium besilate enhances the TRAIL-induced apoptosis of gastric cancer cells via p53 signaling

et al. 2021

View full text Add to dashboard Cite

Cisatracurium besilate is the most commonly used non-depolarizing muscle relaxant in general anesthesia and in intensive care units. Studies have indicated that the proliferation of gastric cancer (GC) cells can be restrained by cisatracurium besilate. The present study aimed to investigate the mechanism underlying the role of cisatracurium besilate in TNF-related apoptosis-inducing ligand (TRAIL)-induced GC. The AGS cell line was exposed to cisatracurium besilate, and then cell viability, colony formation and apoptosis were assessed by performing Cell Counting Kit-8, colony formation, TUNEL and Western blot assays, respectively. Furthermore, the expression levels of p53 and p53 upregulated modulator of apoptosis (PUMA) were measured by Western blotting to determine the effect of cisatracurium besilate on p53/PUMA signaling. After co-treatment with p53 inhibitor, cisatracurium besilate and pifithrin-α/TRAIL, cell apoptosis was detected. Finally, cisatracurium besilate and pifithrin-α were used to co-treat TRAIL-induced AGS cells followed by apoptosis detection. Cisatracurium besilate treatment restrained the proliferation and promoted the apoptosis of AGS cells. Cisatracurium besilate also promoted the expression of p53 and PUMA in AGS cells. Furthermore, TRAIL induced the apoptosis of AGS cells, which was aggravated by cisatracurium besilate treatment. However, pifithrin-α reversed the synergistic effects of cisatracurium besilate and TRAIL on the activities of AGS cells. Therefore, the present study suggested that cisatracurium besilate enhanced the TRAIL-induced apoptosis of GC cells via p53 signaling, and the synergistic effects of cisatracurium besilate and TRAIL may achieve maximal therapeutic efficacy in GC management.

show abstract

“…In oncology surgery, radical surgery is a procedure that can be used to help diagnose and treat a disease by removing a tumor or cluster lymph nodes and capturing their contents. (Such as radical mastectomy) (2,9).…”

Section: Discussionmentioning

confidence: 99%

“…Studies have shown that both anesthetic drugs and anesthesia methods can affect patient prognosis. Cisatracurium is currently one of the most widely used anesthetic-inducing drugs in clinical practice, which can reduce the migration and invasion of esophageal squamous cell carcinoma by inhibiting epithelial-mesenchymal transition (EMT) and TGF-β/Smad signaling pathway (9). So far, the effect of cisatracurium on proliferation, migration and invasion of breast cancer cells remains unknown.…”

Section: Discussionmentioning

confidence: 99%

Cisatracurium inhibits the proliferation, migration and invasion of breast cancer cells by regulating the expression of miR-3174

Yang

2020

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Breast cancer is a type of cancer that begins in the breast tissue. Being a woman is the most important factor in the risk of breast cancer. Although men also get the cancer, women are much more likely to get it. This experiment was founded to investigate the effect and mechanism of Cisatracurium on breast cancer cell proliferation, migration and invasion. Breast cancer cells MDA-MB-231 were cultured in vitro. MDA-MB-231 cells were treated with cisatracurium of different concentrations for 48 h. CCK-8method detected cell proliferation, Transwell detected cell migration and invasion, Western Blot method detected the expression levels of CyclinD1, p21, MMP-2andMMP-9protein in cells, RT-qPCR) detected the expression level of miR-3174in cells. After miR-3174 inhibitor was transfected into MDA-MB-231 in order to down-regulate the expression of miR-3174, the same methods as above were used to observe the effect of the down-regulating miR-3174 expression on MDA-MB-231 cell proliferation, migration and invasion as well as the expression levels of CyclinD1, p21, MMP -2 andMMP-9 protein. After different concentrations of Cisatracurium acted on MDA-MB-231 cells, the cell inhibition rate and p21 protein expression were significantly increased (p<0.05), the number of cell migration and invasion and the expression levels of CyclinD1, MMP-2 and MMP-9 were significantly reduced (p<0.05), and the expression of miR-3174 in cells was significantly reduced (p<0.05). After down-regulating the expression of miR-3174, the cell inhibition rate and p21 protein expression were significantly increased (p<0.05), the number of cell migration and invasion and the expression levels of CyclinD1, MMP-2 and MMP-9 were significantly reduced (p<0.05). Up-regulating miR-3174 expression could reverse the effect of Cisatracurium on the proliferation, migration and invasion of MDA-MB-231 cells. Cisatracurium can inhibit the proliferation, migration and invasion of breast cancer MDA-MB-231 cells, and its mechanism is related to the down-regulation of miR-3174 expression in cells.

show abstract

Effects of cisatracurium on epithelial‑to‑mesenchymal transition in esophageal squamous cell carcinoma

Cited by 7 publications

References 44 publications

Long non‑coding RNA PITPNA‑AS1 silencing suppresses proliferation, metastasis and epithelial‑mesenchymal transition in non‑small cell lung cancer cells by targeting microRNA‑32‑5p

Long non‑coding RNA PITPNA‑AS1 silencing suppresses proliferation, metastasis and epithelial‑mesenchymal transition in non‑small cell lung cancer cells by targeting microRNA‑32‑5p

Cisatracurium besilate enhances the TRAIL-induced apoptosis of gastric cancer cells via p53 signaling

Cisatracurium inhibits the proliferation, migration and invasion of breast cancer cells by regulating the expression of miR-3174

Contact Info

Product

Resources

About